Report an error

Spotted something inaccurate in “Alpibectir Potentiates Low-Dose Ethionamide in Phase 2a TB Trial, Overcoming Toxicity Limitations with Potential Against Resistant Strains”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.